延长无铂间期:在中等铂敏感卵巢癌中省略二线铂类化疗的影响
该多机构回顾性研究纳入177例原发铂类化疗后6-12个月复发的上皮性卵巢癌患者,比较二线铂类与非铂类化疗或靶向治疗的疗效。结果显示,二线铂类化疗的中位PFS2(7.1个月)长于非铂类(3个月,p=0.0114)和靶向治疗(3个月,p=0.0431),中位OS铂类组43.6个月 vs 无铂组37.6个月(p=0.0174)。结论认为,使用非铂类或靶向治疗延长PFI会导致更差的生存。
要点
- 二线铂类化疗中位PFS2为7.1个月,非铂类为3个月(p=0.0114)。
- 二线铂类化疗中位PFS2为7.1个月,靶向治疗为3个月(p=0.0431)。
- 二线含铂 vs 不含铂中位OS为43.6 vs 37.6个月(p=0.0174)。
核心结论
- 在6-12个月复发的上皮性卵巢癌患者中,使用非铂类化疗或靶向治疗延长无铂间期会导致更差的生存。
研究设计与样本
- 多机构回顾性综述,纳入177例原发铂类化疗后6-12个月复发的上皮性卵巢癌患者,比较二线铂类 vs 非铂类化疗或靶向治疗。
主要发现
- 177例患者中多数为白人、浆液性组织学、接受过初次肿瘤细胞减灭术;中位PFI1为8.2个月(95%CI 8-9个月)。
- 28%的患者省略了二线铂类;16%的患者二线使用贝伐珠单抗;19%接受其他靶向治疗。
- 二线铂类化疗的中位PFS2为7.1个月,非铂类为3个月(p=0.0114)。
- 二线铂类化疗的中位PFS2为7.1个月,靶向治疗为3个月(p=0.0431)。
- 二线含铂 vs 不含铂的中位OS为43.6 vs 37.6个月(p=0.0174)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with epithelial ovarian cancer (EOC) recurring between 6 and 12 months after primary platinum chemotherapy have worse prognosis than those recurring in >12 months. Artificially prolonging the platinum-free interval (PFI) with cytotoxic chemotherapy was tested in MITO-8 with poor outcomes. This study aimed to determine the impact of using non-platinum or targeted therapy in 2nd line treatment of EOC patients recurring 6-12 months after completion of primary platinum-based chemotherapy. METHODS: A multi-institutional retrospective review of 177 patients with recurrent EOC and PFI of 6-12 months following primary chemotherapy was performed comparing platinum versus non-platinum chemotherapy or targeted therapy for 2nd line treatment. PFI1 was defined as the date of last chemotherapy to date of recurrence. PFS2/3 were defined as start of 2nd or 3rd line chemotherapy to start of subsequent line. RESULTS: Of 177 patients, the majority of patients were Caucasian, had serous histology, and underwent primary cytoreductive surgery. Median PFI1 was 8.2 months (95% CI 8-9 months). Second line platinum was omitted in 28% of patients. Bevacizumab was used in 2nd line in 16% of patients; 19% received other targeted therapies. Median PFS2 for platinum chemotherapy was longer than non-platinum (7.1 vs 3 months, p = 0.0114). Median PFS2 was significantly longer for platinum vs. targeted therapy (7.1 vs. 3 months p = 0.0431). Median OS for platinum in 2nd line vs. no platinum was 43.6 vs. 37.6 months (p = 0.0174). CONCLUSIONS: Use of non-platinum chemotherapy and even targeted therapy to prolong PFI in patients with EOC recurring between 6 and 12 months leads to worse survival.
引用
- Dockery LE, Rubenstein AR, Ding K, et al. Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer. Gynecol Oncol. 2019. PMID: 31522837. doi:10.1016/j.ygyno.2019.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。